Related Experiment Videos
What's new in heart failure therapy 2018?
Julian G Westphal1, Tarek Bekfani1, Paul Christian Schulze1
1Division of Cardiology, Pneumology, Angiology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Jena, Friedrich-Schiller-University Jena, Jena, Germany.
Insights
Heart failure treatment advances are ongoing, but options for preserved ejection fraction heart failure are limited. Optimizing underlying conditions and comorbidities is crucial for improving patient outcomes.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Therapeutics
Background:
- Heart failure is a major cause of mortality and morbidity, imposing a significant economic burden.
- Limited therapeutic options exist for heart failure with preserved ejection fraction (HFpEF).
- The heterogeneity and debated pathophysiology of heart failure present challenges in patient care.
Purpose of the Study:
- To review current data on heart failure treatment strategies.
- To cover both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
- To incorporate the latest recommendations for medical and interventional therapies.
Main Methods:
- Focused review of recent scientific literature.
- Analysis of current clinical recommendations.
- Synthesis of data on medical and interventional strategies.
Main Results:
- Significant progress in heart failure treatment over three decades.
- Persistent challenges in treating heart failure with preserved ejection fraction (HFpEF).
- Growing evidence supports the role of treating underlying conditions and comorbidities.
Conclusions:
- Optimizing management of underlying conditions and comorbidities is key for improving heart failure outcomes.
- Further research is needed to develop effective therapies for HFpEF.
- Current recommendations emphasize a comprehensive approach to heart failure management.
Abstract:
Even though significant progress has been made over the past 3 decades, heart failure remains one of the leading causes of mortality and morbidity in developed countries and contributes significantly to the economic burden of modern health care systems. Especially in patients with preserved ejection fraction, valid therapeutic options are missing due to a lack of evidence. In face of a very heterogeneous condition with an ongoing debate over aetiology and pathophysiology, clinicians face a challenge in providing optimal care for these patients. Recent data suggest that the optimal treatment of the underlying conditions as well as comorbidities that are associated with heart failure might play an ever increasing role in improving outcomes. This focused review summarizes and reviews current data for the treatment of heart failure with both preserved and reduced ejection fractions based on the latest recommendations covering medical therapy and interventional strategies.